Neurocrine BiosciencesLTS:0K6R +1.97%95 Pretax Margin % is 30.30% as of Mar. 2026, which is 216% above its 10-year median of 9.58. GuruFocus rates LTS:0K6R with a GF Score™ of 95/100 and a GF Value™ of $190.90 (Fairly Valued). The stock has 6 warning signs investors should review. Among 956 Drug Manufacturers companies, Neurocrine Biosciences ranks better than 91.84% on this metric.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Neurocrine Biosciences Pretax Margin % Related Terms
Neurocrine Biosciences Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Neurocrine Biosciences's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0K6R vs VTRS, ELAN, UTHR: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurocrine Biosciences Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Neurocrine Biosciences's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurocrine Biosciences (LTS:0K6R) has a Pretax Margin % of 30.30% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Neurocrine Biosciences and its competitors. This is 216% above median its historical median of 9.58. According to the industry distribution chart, Neurocrine Biosciences ranks #78 out of 956 companies in the Drug Manufacturers industry, placing it in the top 8.2%.
Is Neurocrine Biosciences' Pretax Margin % too high?
Neurocrine Biosciences' current Pretax Margin % of 30.30% is 216% above median its 10-year median of 9.58. The Drug Manufacturers industry median Pretax Margin % is 7.29. Neurocrine Biosciences' value of 30.30% is 315.9% above this industry median. Based on the distribution chart, Neurocrine Biosciences ranks #78 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Neurocrine Biosciences has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' Pretax Margin % compare to VTRS and ELAN?
According to the Drug Manufacturers industry distribution chart, Neurocrine Biosciences ranks #78 out of 956 companies for Pretax Margin %. This places Neurocrine Biosciences in the top 8% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.29. Neurocrine Biosciences' value of 30.30% is 315.9% above this benchmark. While the company's 10-year median is 9.58 vs. the industry median of 7.29, Neurocrine Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.29, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neurocrine Biosciences's current Pretax Margin % of 30.30% is 315.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Neurocrine Biosciences and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurocrine Biosciences's current Pretax Margin % is 30.30%, which is 216% above median its own 10-year median of 9.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (LTS:0K6R) is currently considered Fairly Valued. The stock's GF Value™ is $190.90, compared to a current price of $177.71 — trading 6.9% below its estimated fair value. The current Pretax Margin % is 30.30%, which is 216% above median its 10-year median of 9.58 and 315.9% above the Drug Manufacturers industry median of 7.29. Neurocrine Biosciences' overall GF Score™ is 95/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Neurocrine Biosciences (LTS:0K6R), the current Pretax Margin % is 30.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neurocrine Biosciences (LTS:0K6R) Overvalued in 2026?
Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued.
The current stock price of $177.71 is trading 6.9% below its estimated GF Value™ of $190.90.
GuruFocus considers Neurocrine Biosciences to be Fairly Valued.
Key valuation signals for LTS:0K6R:
Pretax Margin %: 30.30% (216% above median its 10-year median of 9.58)
GF Value™: $190.90 vs. price of $177.71 (6.9% below fair value)
Industry Position: 315.9% above the Drug Manufacturers median (#78 of 956)
No single metric tells the full story. See the LTS:0K6R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
95GF Score
Get the complete analysis for LTS:0K6R
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0K6R has been successfully added to your 
